Staff Members - Benha University
Galectin-3 as a Predictor for Left Ventricular Remodeling After Anterior Wall Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention
Benha Journal of Applied Sciences (BJAS) • 2021
Publication Information
Authors
A.M.Bendary; A.A.Elheet; H. M.Kabil; S.A.Moustafa
Keywords
: Galectin-3, Left Ventricular Remodeling, Anterior Wall Myocardial Infarction
Journal
Benha Journal of Applied Sciences (BJAS)
Publisher
Egyptian Knowledge Bank
Volume
6
Issue
5
Pages
55-62
publication.type
Local
Paper Link
Open Link
Supplementary Materials
Not Available
Abstract
Background: This is a single center, observational prospective study that aimed primarily to study role of
Galectin-3 (as a simple marker of inflammation and fibrosis) in prediction of the occurrence of LV remodeling after
anterior ST-elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (pPCI)
for Left anterior descending artery (LAD) or left main (LM) as infarct related artery. Patients and methods: The
present study protocol yielded 2 groups of patients: First group, consists of patients found to have LVR with high
galectin 3 levels at baseline and 6 months follow up after anterior STEMI treated with primary PCI to LAD or LM.
Second group consists of patients found to have no LVR with low levels of galectin 3 levels at baseline and 6
months follow up after anterior STEMI treated with primary PCI to LAD or LM. Results: Baseline and 6 months EF
were significantly higher in the no LVR (57±8 &55 ±8 respectively) group than the LVR group (44 ±7&37 ±8
respectively), P values were
Galectin-3 (as a simple marker of inflammation and fibrosis) in prediction of the occurrence of LV remodeling after
anterior ST-elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (pPCI)
for Left anterior descending artery (LAD) or left main (LM) as infarct related artery. Patients and methods: The
present study protocol yielded 2 groups of patients: First group, consists of patients found to have LVR with high
galectin 3 levels at baseline and 6 months follow up after anterior STEMI treated with primary PCI to LAD or LM.
Second group consists of patients found to have no LVR with low levels of galectin 3 levels at baseline and 6
months follow up after anterior STEMI treated with primary PCI to LAD or LM. Results: Baseline and 6 months EF
were significantly higher in the no LVR (57±8 &55 ±8 respectively) group than the LVR group (44 ±7&37 ±8
respectively), P values were